With H1/2018A numbers much in line with our expectations, MDxH is building momentum with sustained growth of its Confirm- and SelectMDx prostrate cancer diagnostics. While ConfirmMDx will continue to be the main driver in the shorter term, SelectMDx looks increasingly like the major value driver. Increasing evidence should supports the clinical and economic benefits of SelectMDx throughout prostate cancer therapy from early diagnosis through longer term treatment management and monitoring; a pot ....
31 Aug 2018
Building Momentum
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Building Momentum
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
31 Aug 2018 -
Author:
Chris Redhead -
Pages:
5
With H1/2018A numbers much in line with our expectations, MDxH is building momentum with sustained growth of its Confirm- and SelectMDx prostrate cancer diagnostics. While ConfirmMDx will continue to be the main driver in the shorter term, SelectMDx looks increasingly like the major value driver. Increasing evidence should supports the clinical and economic benefits of SelectMDx throughout prostate cancer therapy from early diagnosis through longer term treatment management and monitoring; a pot ....